NACDS Foundation adds Sara Roszak as research programs director
BY DSN STAFF
ARLINGTON, Va. — The National Association of Chain Drug Stores Foundation announced that it had promoted NACDS pharmacy care and patient advocacy staffer as its new research programs director. Sara Roszak, who joined NACDS in 2014 will oversee expansion of the foundation’s research portfolio, identifying research concepts and priorities, as wel as developing and managing research requests for proposals and grant research projects alongside the foundation’s Research Advisory Working Group.
“We’re pleased to welcome Sara into this new role with the NACDS Foundation,” NACDS Foundation president Kathleen Jaeger said. “Sara has demonstrated leadership in developing innovative research initiatives and securing grant funding. That experience will be invaluable as she moves over to the Foundation and helps to position it as a leader in advancing patient health through medication management and collaborative care.”
The American Public Health Association recognized Roszak Nov. 3 for her work advancing public health with the organization’s Jay S. Drotman Memorial Award. The award is given to professionals and students under 30 who have show potential in the health field by creatively and positively challenging traditional public health or practice.
Diplomat Pharmacy’s quarterly revenue up 59%
FLINT, Mich. – Diplomat Pharmacy on Tuesday posted revenue of $947 million, representing an increase of 59%, for the quarter ended Sept. 30. Total prescriptions dispensed increasated to 245,000, representing growth of 17%.
“[Overall], the 32% growth in organic revenue was our highest organic growth quarter yet this year," commented Phil Hagerman, Diplomat chairman and CEO. "Across the entire organization, this was another very successful quarter as we saw tremendous growth in our core business, including our recent acquisitions, which are performing well ahead of our expectations. We are incredibly excited about our industry and its growth potential," he said. "There remains a rich pipeline of drugs in development that lend themselves to the specialty pharmacy model and I’m very confident in our ability to continue to win access to limited distribution panels. In the wake of such a strong quarter, we are raising our outlook for the remainder of 2015.”
For the full-year 2015, Diplomat Pharmacy now expects revenue between $3.25 and $3.4 billion, up from a previous range of $3.2 to $3.4 billion, and net income between $27 million and $29 million, up from a previous range of $11 million to $13 million.
Loading Post Please Wait...